ADAP stock: buy or sell?
January 17th, 2020
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform.
Should I buy ADAP stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Adaptimmune stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Adaptimmune stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 2 ratings published for ADAP stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
ADAP stock analysis
Adaptimmune Therapeutics shares grew 0.67% to $4.52 today.
Adaptimmune Therapeutics shares grew 0.67% to $4.52 today. Since price and SMA200d lines crossed up on Monday, ADAP climbed $3.19 (239.85%). Today, SMA50d and SMA100d crossed up triggering a rise of 0.67%.
Adaptimmune shares broke up the SMA line of 200d, closing at $4.52. Late December 2019 ADAP plummed a frightening -15.00% in just one week.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $1.44 resistance. Since SMA10d and SMA20w crossed up this week, ADAP price climbed $3.19 per share (239.85%).
ADAP stock price history
ADAP stock went public on May 6th, 2015 with a price of $19.251. Since then, ADAP stock lost a -76.50%, with a yearly average of -19.10%.
1: Adjusted price after possible price splits or reverse-splits.
ADAP stock historical price chart
ADAP stock reached 52-week highs on Tuesday at $6.00, and all-time highs 2015-06-16 with a price of 21.57.
ADAP stock price target is $7.00How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 2 price forecasts for ADAP stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Adaptimmune presented its financial report, posting an exceptional growth for the Earnings per Share (EPS). Analyst expected $-0.29 per share, but Adaptimmune Therapeutics posted $-0.36.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Adaptimmune annual turnover skyrocketed an outstanding 57.28% to $59.51 million USD from $37.83 marked in 2017. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) boosted a 24.87% to -160.51%.
|2014||$825 M||-||$0.00 M0.0%||-|
|2014||$0.58 M||-99.93%||$-12.21 M-2100.9%||0.00%|
|2015||$9.87 M||1,598.45%||$-22.06 M-223.5%||80.66%|
|2015||$8.98 M||-9.04%||$-23.00 M-256.2%||4.27%|
|2016||$14 M||58.12%||$-71.58 M-504.1%||211.21%|
|2017||$38 M||166.47%||$-70.14 M-185.4%||-2.01%|
|2018||$60 M||57.28%||$-95.51 M-160.5%||36.18%|
Quarterly financial resultsAdaptimmune posted $1.48 M in sales for 2018-Q4, a -96.37% less compared to previous quarter. Reported quarter earnings marked $-36.17 million with a profit margin of -2,445.77%. Profit margin collapsed a -2,458.62% compared to previous quarter when profit margin was 12.85%. When comparing revenues to same quarter last year, Adaptimmune Therapeutics sales marked a bloodcurdling drop down and plunged a -65.36%.
|2017-Q1||$3 M||-||$-21.99 M-763.5%||-|
|2017-Q2||$4 M||23.61%||$-20.44 M-574.2%||-7.05%|
|2017-Q3||$27 M||663.62%||$-0.88 M-3.2%||-95.70%|
|2017-Q4||$4 M||-84.29%||$-27.26 M-638.5%||3,005.13%|
|2018-Q1||$8 M||91.94%||$-21.08 M-257.2%||-22.69%|
|2018-Q2||$9 M||10.27%||$-43.85 M-485.1%||108.01%|
|2018-Q3||$41 M||351.34%||$5.24 M12.9%||-111.96%|
|2018-Q4||$1 M||-96.37%||$-36.17 M-2445.8%||-790.06%|
Adaptimmune ownershipWhen you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.
Adaptimmune Therapeutics shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.24% of all shares.
In case of Adaptimmune Therapeutics stock, 71.92% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ADAP stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Adaptimmune:
|Market cap||$475.4 M||$129.4 M||$2.9 B||$1.0 B|
|Total shares||105.2 M||47.6 M||43.6 M||115.9 M|
|Float shares||53.2 M||35.1 M||31.3 M||115.8 M|
|- Institutional holdings (%)||71.9%||69.5%||88.3%||72.2%|
|- Insider holdings (%)||0.2%||7.7%||8.1%||0.5%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
|Friday, January 17th, 2020|
|Day range||$4.30 - $4.82|
|Average true range||$0.70|
|50d mov avg||$1.43|
|100d mov avg||$1.39|
|200d mov avg||$2.45|
Adaptimmune performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Adaptimmune Therapeutics against Enzo Biochem, uniQure and Sangamo Therapeutics in the following table: